Dr. Sukhovolskiy is a staff optometrist at Pacific Cataract & Laser Institute, a surgical co-management company in the Pacific Northwest. He works in the Tacoma, Washington, clinic.

is a staff optometrists at Pacific Cataract & Laser Institute, a surgical co-management company in the Pacific Northwest. He works in the Tualatin, Oregon, clinic.

Articles

Advancements in medications and lasers bring better adherence and outcomes.

New treatments and surgeries are transforming the glaucoma landscape 

Signs of the SARS-CoV-2 virus in human ocular tissues samples post-mortem were found to be low in samples considered suitable for corneal recovery and transplantation.

Eye bank samples show low prevalence of SARS-CoV-2 

Acute corneal endothelial rejection is a possibility soon after either the first or second dose of the COVID-19 messenger RNA (mRNA) vaccine (Moderna), according new research.

Corneal transplant rejection following COVID-19 vaccination

Transitions Optical's Diversity Advisory Board members share how eyecare professionals can incorporate diversity, equity and inclusion in their lives and careers.  

Transitions Optical recognizes diversity, equity, inclusion 

Podcasts

Open your eyes: ocular emergencies 

AACO will once again be participating in a co-located meeting at SECO 2022 in New Orleans, March 9-13. AACO will be presenting 4 hours of FREE CE as well as a CE Dinner open to all Optometrists, free for AACO members.

AACO Dinner & CE Event: what to know 

Expand your business by administering injectable treatments.

Incorporating injections into your practice

Danish researchers report a significantly increased association between the mRNA-1273 vaccination (Moderna) and development of myocarditis or myopericarditis.

Study: myocarditis/myopericarditis linked to COVID-19 vaccinations

ASCENT, RegenXBio’s Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada, with pivotal trials expected to support BLA submission for RGX-314 in 2024.

RGX-314 clinical program: second pivotal trial to begin

A review of monitoring guidelines, risk assessment, and treatment algorithms.